Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy.

Literature DB >> 24666021

Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy.

Michael Starck¹, Clemens-Martin Wendtner.

Abstract

Entities: Chemical Disease

Keywords: eculizumab; gemcitabine; plasma exchange; rituximab; thrombotic microangiopathy

Year: 2013 PMID： 24666021 DOI： 10.1111/bjh.12686

Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

1. Neurological variability in chemotherapy-induced posterior reversible encephalopathy syndrome associated with thrombotic microangiopathy: Case reports and literature review.

Authors: Chen Makranz; Salome Khutsurauli; Yosef Kalish; Ruth Eliahou; Luna Kadouri; John Moshe Gomori; Alexander Lossos
Journal: Mol Clin Oncol Date: 2017-11-02

2. Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.

Authors: Maximilien Grall; Florence Daviet; Noémie Jourde Chiche; François Provot; Claire Presne; Jean-Philippe Coindre; Claire Pouteil-Noble; Alexandre Karras; Dominique Guerrot; Arnaud François; Ygal Benhamou; Agnès Veyradier; Véronique Frémeaux-Bacchi; Paul Coppo; Steven Grangé
Journal: BMC Nephrol Date: 2021-07-21 Impact factor: 2.388

3. The use of eculizumab in gemcitabine induced thrombotic microangiopathy.

Authors: Vinod Krishnappa; Mohit Gupta; Haikoo Shah; Abhijit Das; Natthavat Tanphaichitr; Robert Novak; Rupesh Raina
Journal: BMC Nephrol Date: 2018-01-12 Impact factor: 2.388

4. Eculizumab in secondary atypical haemolytic uraemic syndrome.

Authors: Teresa Cavero; Cristina Rabasco; Antía López; Elena Román; Ana Ávila; Ángel Sevillano; Ana Huerta; Jorge Rojas-Rivera; Carolina Fuentes; Miquel Blasco; Ana Jarque; Alba García; Santiago Mendizabal; Eva Gavela; Manuel Macía; Luis F Quintana; Ana María Romera; Josefa Borrego; Emi Arjona; Mario Espinosa; José Portolés; Carolina Gracia-Iguacel; Emilio González-Parra; Pedro Aljama; Enrique Morales; Mercedes Cao; Santiago Rodríguez de Córdoba; Manuel Praga
Journal: Nephrol Dial Transplant Date: 2017-03-01 Impact factor: 5.992

Review 5. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

Authors: Arif Asif; Ali Nayer; Christian S Haas
Journal: J Nephrol Date: 2016-11-15 Impact factor: 3.902

Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy.

1. Neurological variability in chemotherapy-induced posterior reversible encephalopathy syndrome associated with thrombotic microangiopathy: Case reports and literature review.

2. Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.

3. The use of eculizumab in gemcitabine induced thrombotic microangiopathy.

4. Eculizumab in secondary atypical haemolytic uraemic syndrome.

Review 5. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

6. Eculizumab in chemotherapy-induced thrombotic microangiopathy.

7. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

8. IgA-Dominant Glomerulopathy and Thrombotic Microangiopathy After Chemotherapy.